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S240 Poster Session Itransplantation (ASCT) at our institute till december, 2007. Pa-
tients’ median age was 52 years (range, 26 to 68 years). High
dose melphalan (200 mg/m2) was used for conditioning. 86
(72.8%) patients had evidence of chemo-sensitive disease prior
to transplant. Response was defined as per EBMT criteria. Fol-
lowing ASCT 80.5% of patients responded; complete (CR) –
46(39%), very good partial response-31(26.3%), and partial re-
sponse-18(15.3%). CR rate was higher for patients with chemo-
sensitive disease; 44 of 86 patients (51.0%) achieved CR com-
pared to 2 of 32 patients (6.2%) with chemo-resistant disease,
p\.001. Response rate to transplant was higher for patients
with serum albumin. 3.3 mg% (p5 0.03), ISS stage- I-II at di-
agnosis (p5 0.001) and Durie-Salmon stage IIIA, p5 0.001. At
a median follow up of 83 months (range, 22 to 155 months),
the median overall (OS) and event-free survival (EFS) is 72
and 29 months, respectively. Estimated OS and EFS at 60
months is 54.2% 6 0.05% (SE) and 32% 6 0.05(SE), respec-
tively. Patients who achieved CR (median not reached yet,
mean 171.91 months +/- 16.2 (SE)) and very good PR (median
84 months) following transplant had a significantly better survival
compared to those with PR (median 38 months,p5 0.0001). Pre-
transplant chemo-sensitive disease (OS: p5 0.006, EFS:
p5 0.007), ISS stage I-II (EFS: p5 0.008) and response to trans-
plant (OS and EFS: p5 0.0001) were important predictors of
survival on multivariate analysis. Six patients (Four disease-free)
were alive at .120 months follow up; all six had pre-transplant
chemo-sensitive disease and had achieved CR after transplant.
Conclusion: Patients with pre-transplant chemo-sensitive disease
and those who achieve complete response following transplant ben-
efit maximum.221
HIGH-DOSE THERAPY AND AUTOLOGOUS HEMATOPIETIC PROGENITOR
CELL TRANSPLANTATION FOR RECURRENT OR REFRACTORY HODG-
KIN’S LYMPHOMA: ANALYSIS OF KING HUSSEIN CANCER CENTER
(KHCC) RESULTS AND PROGNOSTIC VARIABLES
Abdel-Rahman, F.A., El Taani, H.A., Badheeb, A., AlJmili, M., El-
Khatib, H.M., Ahmed, A., Alzabin, A., Rihani, R., Hussein, N.,
Sarhan, M. King Hussein Cancer Center, Amman, Jordan
Purpose: to evaluate the outcome of patients with Hodgkin’s lym-
phoma who underwent autologus hematopoietic stem cell transplan-
tation at the young KHCC bone marrow transplant (BMT)
program.
Patients and Methods: Over the past 6 years, 63 patients with re-
lapsed or refractory Hodgkin’s lymphoma underwent high dose che-
motherapy followed by autologus stem cell transplant. Among the
group there were 54 adults, and 9 children. The median age was
27 years, and 61% of the patients were males.
There were 16 (25.4%) patients in complete remission (CR), 45
(71.4%) with chemotherapy responsive disease and 2 patients (3%)
with stable disease. Prior to conditioning regimen, 35 patients
(56%) received two chemotherapy lines only, and 28 patients
(44%) received more than two lines.
All patients except three received BEAM as pre transplant condi-
tioning.
Results: the main end points of the study are the rate of complete
remission at day 100, overall survival(OS), relapse-free survival
(RFS), correlation of the following variables with OS and RFS: a-dis-
ease status at the time of transplant, b-number of chemotherapy lines
prior to conditioning c-age group.
The median follow up time was 16.0 months (range, 1.25-
44.4months).
The day 100 non-relapse mortality was 4.8%.
The CR at day 100 was 57% (25% before transplant).The median
overall survival for the whole group were 40.6 months, the median
RFS was not reached but currently 63% are still relapse-free.
When we looked at the three variables in correlation with OS,
and RFS in aunivarient analysis, the only statistically significant
correlation was between the number of chemotherapy lines prior
to conditioning and OS, with p value 0.049 in favor of patients
received two lines only. In all other correlations the p value
was not significant.Conclusion: Despite its young age, our program is able to perform
autologous stem cell transplantation for Hodgkin Disease at a reason-
ably acceptable mortality and with an outcome comparable to pub-
lished data.
In our study only the number of chemotherapy lines received be-
fore conditioning had statistically significant correlation with OS.
The disease status at the time of transplant did not have statisti-
cally significant correlation with survival, this is contradicting
some of the published literature, however; this could be mainly
due to the small number of patients, 16 (25%): CR and 45
(71.4%): responsive disease. A complete analysis of data will be pre-
sented at the meeting.PEDIATRIC DISORDERS
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STEM CELL TRANSPLANTATION FOR NIJMEGEN BREAKAGE SYNDROME
Albert, M.H.1, Gennery, A.R.2, Greil, J.3, Cale, C.M.4, Kalwak, K.5,
Kondratenko, I.6, Mlynarski, W.7, Stachel, D.K.8, Notheis, G.1,
Fu¨hrer, M.1, Schmid, I.1, Belohradsky, B.H.1 1Dr. von Haunersches
Kinderspital, Munich, Germany; 2Newcastle General Hospital, Newcastle,
United Kingdom; 3University Hospital, Heidelberg, Germany; 4Great
Ormond Street Hospital, London, United Kingdom; 5Pediatric Hematolo-
gy/Oncology/BMT,Wroclaw, Poland; 6Russian Children’s Clinical Hospi-
tal, Moscow, Russian Federation; 7Medical University of Lodz, Lodz,
Poland; 8Kinderklinik der Universita¨t, Erlangen, Germany
Nijmegen breakage syndrome (NBS) is a rare autosomal recessive
disorder characterized by immunodeficiency, characteristic facial ap-
pearance, chromosomal instability, X-ray hypersensitivity, and pre-
disposition to malignancy. About 40% of patients develop
malignancy mostly of lymphoid origin before age 21. Traditionally
NBS patients have not undergone stem cell transplantation (SCT)
owing to concerns about chromosomal instability and increased tox-
icity. But in the case of resistant or relapsing malignancy SCT may be
the only therapeutic option. We therefore analyzed the transplant
experience in NBS patients in Europe.
A total of six genetically confirmed NBS patients were included.
Median age at diagnosis was 7.6 years (range 1-18) and 14.5 years
(range 2.3-20.3) at transplant. The reason to attempt SCT was resis-
tant or secondary malignancy in four cases. The other two were
transplanted because of severe immunodeficiency or suspected Fan-
coni anemia with immunodeficiency. All had a quantitative and func-
tional T-cell defect and 4/6 had deficient humoral immunity before
transplant. Five patients received reduced intensity regimens with in
vivo T-cell depleting agents. The donors were MSD in 3 patients,
one haploidentical parent and two MUD.
At a median follow up of 3.0 years (range 2.4-9.1) five of six pa-
tients are alive and well. Three patients had no relevant transplant re-
lated complications. One patient died on day +5 from sepsis. He had
received a BMT from a matched sibling after a myeloablative, busul-
fan containing conditioning regimen. Acute GVHD grade I-II oc-
curred in 3/5 patients, mild chronic GVHD in one. Four patients
have complete donor chimerism, one has mixed chimerism, but all
five exhibit restored T-cell immunity.
Although very limited, the experience in these six patients clearly
suggests that SCT in NBS is feasible, can correct the immunodefi-
ciency and effectively treat malignancy. Acute toxicity seems to be
reasonable with reduced intensity conditioning regimens.However,
valid concerns remain about increasing the risk for subsequent ma-
lignancy through cytotoxic agents in these patients.223
POSTGRAFTING IMMUNE SUPPRESSION COMBINEDWITH NONMYELOA-
BLATIVE CONDITIONING FOR TRANSPLANTATION OF HLA-MATCHED
RELATED OR UNRELATED HEMATOPOETIC CELL GRAFTS: PRELIMINARY
RESULTS OF A PHASE II STUDY FOR TREATMENT OF PRIMARY IMMUNO-
DEFICIENCY DISORDERS
Burroughs, L.1,2, Storb, R.1,2, Leisenring, W.1, Torgerson, T.2,
Nemecek, E.3, Frangoul, H.4, Walters, M.5, Scharenberg, A.2,
Rawlings, D.2, Skoda-Smith, S.2, Ochs, H.2,Woolfrey, A.1,2 1FredHutch-
inson Cancer Research Center, Seattle, WA; 2University of Washington
School of Medicine; 3Oregon Health & Sciences University; 4Vanderbilt
University; 5Children’s Hospital, Oakland, CA
Poster Session I S241Myeloablative conditioning regimens may cause life threatening
transplant related toxicities in patients with primary immunodefi-
ciency disorders (PID), particularly in patients with co-morbid con-
ditions. We previously reported the outcomes of a phase I study
using nonmyeloablative conditioning in 14 high-risk patients and
demonstrated low transplant related mortality (TRM; 3-year,
23%); however there was a high incidence of chronic GVHD (1-
year 47%). We reasoned that the incidence of GVHD could be re-
duced if marrow was used instead of PBSC; however, previous expe-
rience showed marrow to be associated with a higher risk for
rejection. Therefore our standard nonmyeloablative regimen of
90 mg/m2 fludarabine and 2 Gy total body irradiation (TBI) was
somewhat intensified to include either Campath 1-H, or, for patients
with infections for whom Campath 1-H was contraindicated, an ad-
ditional 2 Gy TBI.
Sixteen patients with PID and significant underlying infections
and/or other co-morbidities were given HLA-matched related
(n5 7) or unrelated (n5 9) marrow grafts following nonmyeloabla-
tive conditioning modified with either Campath 1-H (n5 3) or 4 Gy
TBI (n5 13). All patients were given postgrafting immunosuppres-
sion with MMF and CSP. Of the 15 patients evaluable for engraft-
ment, mixed (50-95%; n5 8) or full (.95%; n5 6) donor
CD3 + T-cell chimerism was established in 14 patients. Two patients
required a 2nd myeloablative HCT due to graft rejection or loss of
the granulocyte and NK cell components of the graft despite stable
mixed T-cell chimerism. The cumulative incidence of extensive
chronic GVHD at 1 year was 29%. With a median follow-up of 19
(range, 3 – 36) months the 1-year overall survival and TRM were
87% and 14%, respectively. One patient with disseminated CMV
and adenovirus before HCT died from these infections at day +1
and one patient with pre existing renal failure died at day +222
from complications of renal failure. Five patients were not evaluable
for disease response due to less than 100 days of follow-up (n5 2),
2nd HCT (n5 2), or death prior to day 100 following HCT
(n5 1). Eleven patients had improvement in or correction of their
underlying immunodeficiency. Although preliminary, these results
indicate that outcome can be improved for high-risk patients with
PID using a modified nonmyeloablative conditioning regimen and
marrow grafts, resulting in reduction of chronic GVHD, stable do-
nor engraftment, low TRM, and correction of underlying disease
processes.224
CLINICAL OUTCOMES OF PEDIATRIC PATIENTS REQUIRING INTENSIVE
CARDIOPULMONARY SUPPORT DURING HSCT
Duncan, C.N.1, Moffet, J.2, Tamburro, R.3, Steiner, M.4, Morrison, R.5,
Hall, M.6, Herschberger, A.7, Petroviv, A.7, Lehmann, L.1,
McArthur, J.8 1Dana-Farber Cancer Institute, Boston, MA; 2Duke Uni-
versity Medical Center, Durham, NC; 3Penn State, Hershey, PA; 4Uni-
versity of Minnesota Medical Center, Minneapolis, MN; 5St. Jude
Children’s Research Hospital, Memphis, TN; 6Nationwide Children’s
Hospital, Columbus, OH; 7All Children’s Hospital, St. Petersburg, FL;
8Medical College of Wisconsin, Milwaukee, WI
This is a multi-center, case controlled, retrospective study of the
short-term and 1-year outcomes of children who received intensive
cardiopulmonary (CP) support during the HSCT admission at seven
tertiary care facilities. Intensive CP support was defined as the need
for continuous positive pressure ventilation, dopamine greater than
or equal to10 mcg/kg/min, or the use of other cardiotropic drug.
We compared the outcomes of 94 patients who required intensive
CP care to 282 patients hospitalized during the same period who
did not receive intensive CP support. Demographic and transplant
data are summarized below. Respiratory failure was the most com-
mon indication for CP care (75.5%) followed by sepsis (10.6%), neu-
rologic event (4.3%), cardiac compromise (2.1%), multi-system
organ failure (MSOF) (2.1%), and other causes (5.4%). Acute
GVHD was present in 21% of patients and macroscopic bleeding
in 26% at the onset of CP support. 46% of patients had a pediatric
logistic organ dysfunction score of at least 1 in two organ systems
at the start of CP support. 44% of patients needed noninvasive ven-
tilation (median duration 2 days). Of this 44%, 66% later required
invasive ventilation, 22% successfully discontinued support, and
12% died. 82% of CP patients received invasive ventilation (medianduration 8 days) and 38% died prior to discharge. 50% of patients
needed cardiac medications. The median duration CP support was
18.6 days. 44.7% of patients died prior to discharge from CP sup-
port, 52.1% transitioned to non-intensive CP care, and 3.2% re-
turned to the HSCT unit for palliation. MSOF was the most
common cause of death (51%). 39% of patients who survived initial
CP support needed additional intensive CP care and 58% of these
patients died prior to discharge. Survival to hospital discharge was
37.2% in the CP group and 98.9% in the non-CP group. OS at 1-
year was 32% and 78% in the CP and non-CP groups. The 1-year
overall survival (86% vs. 79%) and disease-free survival (69% vs
72%) of CP and non-CP patients who survived to hospital discharge
were not significantly different. The 1-year relapse rate, incidence of
GVHD, mean FEV1, shortening fraction, and creatinine were not
significantly different between the two groups. The survival rate of
pediatric patients requiring intensive CP support has improved,
but remains suboptimal. No significant difference existed in 1-year
organ function or survival among patients who did or did not receive
intensive CP support.
Demographic and Transplant Data
Case, n5 94 Control, n5 282Age median (months) 67 97
Diagnosis (%)ALL CR1/CR2 5.3/12.8 8.9/17
AML CR1/CR2 7.4/5.3 11/8.5
Metabolic Disease 12.8 8.5
Immunodeficiency 1.7 4.3
Nonmalignant Hematologic
Disease10.6 9.5Solid Tumor 13.8 17.7
Myelodysplasia 2.1 1.8
HLH 6.4 0.7
Lymphoma 4 5
Osteopetrosis 3.2 0.4
JMML 2.1 0.7
Other 5.3 6.5
Autolgous HSCT 18.1 18.4
Allogeneic HSCT 81.9 81.5Donor Source (%)
6/6 Related Donor 14.3 35.8
\ 6/6 Related Donor 9.1 6.6
6/6 Unrelated Donor 26 26.2
\6/6 Unrelated Donor 50.6 31.4225
TARGETED BIOLOGICAL THERAPY FOR HEMOPHAGOCYTIC LYMPHOHIS-
TIOCYTOSIS IN A MURINE DISEASE MODEL
Johnson, T.S.1,2, Terrell, C.E.2, Jordan, M.B.1,2 1Cincinnati Children’s
Hospital Medical Center, OH; 2Cincinnati Children’s Hospital Medical
Center, OH
Hemophagocytic lymphohistiocytosis (HLH) is a rare and usually
fatal hyperinflammatory disorder associated with genetic defects of
CD8 + T cell and NK cell cytotoxic function. Jordan, et al (Blood
2004;104(3):735-43) previously showed that perforin-deficient
(prf-/-) mice infected with lymphocytic choriomeningitis virus
(LCMV) develop a disorder which is essentially identical to human
HLH. In this animal model of HLH, ineffective cytotoxic
CD8 + T cells fail to down-modulate stimulatory signals from anti-
gen presenting cells. Exaggerated T cell responses are responsible
for massive cytokine production, especially interferon-gamma
(IFN-g), which drives systemic macrophage activation and results
in HLH-like disease pathology. Thus, at least three critical events
occur in the pathogenesis of HLH: 1) abnormal increase in antigen
presentation, 2) abnormal increase in CD8 + T cell activation and cy-
tokine secretion, and 3) pathological macrophage activation.
Survival with current standard HLH therapy, consisting of cyto-
toxic chemotherapy (etoposide) and nonspecific immunosuppression
(dexamethasone), is approximately 75% at 8 weeks. Ongoing studies
using our murine model of HLH indicate that etoposide acts primar-
ily by deleting activated IFNg-producing T cells. While beneficial in
